Candesartan's Effects on Alzheimer's Disease And Related Biomarkers

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

August 17, 2020

Study Completion Date

August 17, 2020

Conditions
Mild Cognitive Impairment
Interventions
DRUG

Placebo

A matched placebo will be given once daily for 12 months.

DRUG

Candesartan

Candesartan will be started at 8 mg orally, once daily. The dose will be increased in 2 week increments to 16 mg and 32 mg orally, once a day, as long as SBP\>100 mm Hg, DBP\>40 mm Hg and there are no reported symptoms of hypotension (dizziness or weakness). Candesartan will be given for a total of 12 months.

Trial Locations (2)

30322

Emory University, Atlanta

30329

Wesley Woods Center, Atlanta

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Emory University

OTHER

NCT02646982 - Candesartan's Effects on Alzheimer's Disease And Related Biomarkers | Biotech Hunter | Biotech Hunter